Genscript Biotech (HKG:1548) posted an attributable net loss of $129.3 million for the first half, widening from a reported loss of $24.5 million a year earlier.
Loss per share stood at $0.0592, compared with $0.0216 in the year-ago period, according to a Sunday filing with the Hong Kong Exchange.
Revenue increased year over year to $404.2 million for the six months ended June 30 from $518.8 million.
Sands China (HKG:1928) recorded a 3.6% decline in profit attributable to equity holders in the first half to $398 million from $413 million a year prior.Earnings per share slipped to $0.0492 from $0.051 previously, according to a Friday Hong Kong bourse filing.Net revenue increased 11% to $3.88 billion from $3.49 billion in the year-ago period.The company declared an interim dividend of HK$0.50 per share for the period, payable Oct. 9 to shareholders of record as of Sept. 18.
Longfor (HKG:0960) expects profit attributable to owners of between 1.8 billion yuan and 2 billion yuan for the six months ended June 30, down from 3.22 billion yuan a year prior.The property developer attributed the forecast to a continued decline in recognized revenue from the property development business and pressure on the recognized gross profit margin.
Metallurgical Corp. of China (SHA:601618, HKG:1618), or MCC's, newly-signed contract value for the seven months ended July 31 stood at around 447.5 billion yuan.Of the total, the value of newly-signed overseas contracts reached roughly 39.1 billion yuan, according to a Friday Hong Kong bourse filing.